Delving into the Latest Updates on Tiloronoxim Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

盐酸替洛欧, 盐酸替络欧, 盐酸替络肟

+ [2]

Target-

Mechanism-

Therapeutic Areas

Digestive System DisordersRespiratory DiseasesOther Diseases

Active Indication

SilicosisLiver CirrhosisPulmonary Fibrosis

Inactive Indication-

Originator Organization

Chinese Center For Disease Control & Prevention

Active Organization

Chinese Center For Disease Control & Prevention

Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and PreventionBeijing Zhongcheng Jianxin Trading Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study intends to conduct a pharmacokinetic study on oral administration of Tiloxime Hydrochloride Tablets developed by the Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, in healthy Chinese male volunteers, with the aim of providing accurate in vivo metabolic parameters and experimental basis for the design of clinical dosing regimen and dosage determination of Tiloxime Hydrochloride Tablets.

Start Date24 Oct 2005

Sponsor / Collaborator

Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention

[+1]

100 Clinical Results associated with Tiloronoxim Hydrochloride

Login to view more data

100 Translational Medicine associated with Tiloronoxim Hydrochloride

Login to view more data

100 Patents (Medical) associated with Tiloronoxim Hydrochloride

Login to view more data

2

Literatures (Medical) associated with Tiloronoxim Hydrochloride

01 Feb 2010·Journal of Chromatography BQ3 · MEDICINE

Performance of tiloronoxim and tilorone determination in human blood by HPLC–MS/MS: Method validation, uncertainty assessment and its application to a pharmacokinetic study

Q3 · MEDICINE

Article

Author: Yiheng Yang ; Xianhua Zhang ; Suodi Zhai ; Jingli Duan ; Li Yang

A highly sensitive and selective HPLC-MS/MS method is presented for the quantitative determination of tiloronoxim and its metabolite tilorone in human blood. An aliquot of 200 microl human blood was extracted with a mixture of chloroform/ethyl ether (1/2, v/v), using metoprolol as the internal standard (the IS). Separation was achieved on an Xterra MS C18 column (50 mm x 2.1 mm, 5 microm) with a gradient mobile phase of methanol/water containing 15 mM ammonium bicarbonate (pH 10.5). Detection was performed using positive MRM mode on a TurboIonSpray source. The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively. The method was fully validated using total error theory, which is based on beta-expectation tolerance intervals and include trueness and intermediate precision. The method was found to be accurate over a concentration range of 1-100 ng/ml for both compounds. The measurement uncertainty based on beta-expectation tolerance intervals was assessed at each concentration level of the validation standards. This method was successively applied to a pharmacokinetic study of tiloronoxim in healthy volunteers.

15 Nov 2008·Journal of Chromatography BQ3 · MEDICINE

Simultaneous quantification of tiloronoxim and tilorone in human urine by liquid chromatography–tandem mass spectrometry

Q3 · MEDICINE

Article

Author: Xianhua Zhang ; Jingli Duan ; Suodi Zhai ; Li Yang

A simple, sensitive and specific HPLC method with tandem mass spectrometry (HPLC/MS/MS) detection has been developed and validated for the simultaneous quantification of tiloronoxim and its major active metabolite, tilorone, in human urine. The analytes, together with metoprolol, which was employed as an internal standard (IS), were extracted with a mixture solvent of chloroform/ethyl ether (1/2, v/v). The chromatographic separation was performed on a narrow-bore reversed phase HPLC column with a gradient mobile phase of methanol/water containing 15 mM ammonium bicarbonate (pH 10.5). The API 3,000 mass spectrometer was equipped with a TurboIonSpray interface and was operated on positive-ion, multiple reaction-monitoring (MRM) mode. The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively. The assay exhibited a linear dynamic range of 1-100 ng/ml for both tiloronoxim and tilorone based on the analysis of 0.2 ml aliquots of urine. The lower limit of quantification was 1 ng/ml for both compounds. Acceptable precision and accuracies were obtained for concentrations over the standard curve ranges. Run time of 8 min for each injection made it possible to analyze a high throughput of urine samples. The assay has been successfully used to analyze human urine samples from healthy volunteers.

100 Deals associated with Tiloronoxim Hydrochloride

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Silicosis	Phase 2	CN	Beijing Zhongcheng Jianxin Trading Co., Ltd.	31 Oct 2017
Silicosis	Phase 2	CN	Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention	31 Oct 2017
Liver Cirrhosis	Phase 2	CN	Chinese Center For Disease Control & Prevention	-
Pulmonary Fibrosis	Phase 2	CN	Chinese Center For Disease Control & Prevention	-